{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T01:03:31.446616+00:00","company":{"ticker":"CRMD","cik":1410098,"company_name":"CorMedix Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"ma_transaction","fact_key":"2bcb77f8c5ed5b40378b753865cbc05f5783b7be","cik":1410098,"ticker":"CRMD","company_name":"CorMedix Inc.","filed_at":"2025-09-02T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2025-08-29","consideration_text":"$260 million in cash and $40 million worth of common shares","counterparty":"Melinta Therapeutics, LLC","effective_date":"2025-08-29","item_codes_triggered":["2.01","5.01"]},"claim":"CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).","evidence_excerpt":"at the effective time of the Merger (the “Effective Time”), the Company\n(i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject\nto adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared\nto the Working Capital","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-082956","anchor_url":"https://secwatch.observer/filing/0001213900-25-082956#claim-2bcb77f8c5ed5b40378b753865cbc05f5783b7be","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm"},{"fact_type":"earnings_release","fact_key":"3336fbac30ae79aa6593016d7e7b569c6e001511","cik":1410098,"ticker":"CRMD","company_name":"CorMedix Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.25 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $14.5 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.","evidence_excerpt":"CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-041026","anchor_url":"https://secwatch.observer/filing/0001213900-24-041026#claim-3336fbac30ae79aa6593016d7e7b569c6e001511","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm"},{"fact_type":"earnings_release","fact_key":"ba8f8b460fe46401af3830bc0e98b8bef8559e8e","cik":1410098,"ticker":"CRMD","company_name":"CorMedix Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":"$0.91 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$46.3 million, or $0.91 per share","period_text":"the fourth quarter and full year ended December 31, 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":null},"claim":"CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.","evidence_excerpt":"For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-021573","anchor_url":"https://secwatch.observer/filing/0001213900-24-021573#claim-ba8f8b460fe46401af3830bc0e98b8bef8559e8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm"}]}